TempraMed Granted U.S. Patent for Pen Agnostic, VIVI Cap Smart(TM) Further Strengthens Global Intellectual Property Position

Die Übersetzung ist noch nicht verfügbar. Der Originalartikel wird angezeigt.

Patent Grant in the U.S. marks a major milestone in global IP strategy, advancing protection of its VIVI Cap Smart(TM) platform Highlights U.S. patent officially granted by the U.S. Patent Office on September 29, 2026 Covers core innovations underpinning TempraMed's VIVI Cap Smart™, which was launched earlier this year Strengthens the Company's global intellectual property position with 39 granted patents and registered designs across multiple jurisdictions, in addition to pending patent and design applications TempraMed portfolio now available across McKesson Medical-Surgical's U.S. B2B network, including Optum Now, physician offices, long-term care and home health, under an expanded agreement signed in June 2026 Online B2C distribution in the U.S.